CN103980194B - 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 - Google Patents

6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 Download PDF

Info

Publication number
CN103980194B
CN103980194B CN201410204002.2A CN201410204002A CN103980194B CN 103980194 B CN103980194 B CN 103980194B CN 201410204002 A CN201410204002 A CN 201410204002A CN 103980194 B CN103980194 B CN 103980194B
Authority
CN
China
Prior art keywords
quinoline
ethyl
compound
formyloxy
arh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410204002.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103980194A (zh
Inventor
黄文海
沈正荣
杨叶伟
马臻
王尊元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Academy of Medical Sciences
Original Assignee
Zhejiang Academy of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Academy of Medical Sciences filed Critical Zhejiang Academy of Medical Sciences
Priority to CN201410204002.2A priority Critical patent/CN103980194B/zh
Publication of CN103980194A publication Critical patent/CN103980194A/zh
Priority to PCT/CN2015/078918 priority patent/WO2015172722A1/zh
Application granted granted Critical
Publication of CN103980194B publication Critical patent/CN103980194B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • C07D215/34—Carbamates
CN201410204002.2A 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 Active CN103980194B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201410204002.2A CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
PCT/CN2015/078918 WO2015172722A1 (zh) 2014-05-15 2015-05-14 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410204002.2A CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN103980194A CN103980194A (zh) 2014-08-13
CN103980194B true CN103980194B (zh) 2016-09-07

Family

ID=51272391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410204002.2A Active CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN103980194B (nl)
WO (1) WO2015172722A1 (nl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980194B (zh) * 2014-05-15 2016-09-07 浙江省医学科学院 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
CN107417574B (zh) * 2017-03-21 2019-12-03 浙江省医学科学院 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260784A (zh) * 1997-06-17 2000-07-19 达尔文发现有限公司 作为pdeiv和tnf抑制剂的喹啉衍生物
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8－羟基喹啉衍生物
CN103298790A (zh) * 2010-08-13 2013-09-11 维里奈奥公司 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070394A1 (en) * 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
WO2010086860A2 (en) * 2009-01-29 2010-08-05 Yeda Research And Development Co. Ltd. Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them
CA2796967C (en) * 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103980194B (zh) * 2014-05-15 2016-09-07 浙江省医学科学院 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260784A (zh) * 1997-06-17 2000-07-19 达尔文发现有限公司 作为pdeiv和tnf抑制剂的喹啉衍生物
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8－羟基喹啉衍生物
CN103298790A (zh) * 2010-08-13 2013-09-11 维里奈奥公司 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aqueous DMF-potassium carbonate as a substituted for thallium and silver additives in the palladium-catalyzed conversion of aryl bromides to acetyl arenes;Karl S. A. Vallin等;《The journal of organic chemistry》;20010522;第66卷(第12期);第4340－4343页 *

Also Published As

Publication number Publication date
WO2015172722A1 (zh) 2015-11-19
CN103980194A (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
Huang et al. Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities
ES2927888T3 (es) Análogos de pridopidina, su preparación y uso
US9814706B2 (en) Hydrobromide salt of pridopidine
JP6373280B2 (ja) イミダゾピリジン化合物及びその使用
Jia et al. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors
ES2297205T3 (es) Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica.
Zajdel et al. Quinoline-and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor—5-HT1A/5-HT2A/5-HT7 and D2/D3/D4—agents: The synthesis and pharmacological evaluation
EP1979318A1 (en) Amido compounds and their use as pharmaceuticals
CA2663280A1 (en) Diaryl piperidine compounds as calcium channel blockers
FI90534C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1,4-disubstituoitujen piperidinyylijohdannaisten valmistamiseksi
CN103980194B (zh) 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
CN107793408B (zh) 哌啶氨基衍生物及其治疗精神分裂症的应用
Nencetti et al. Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors
CN102786467A (zh) 一种n-取代芳基吡啶酮化合物及其制备方法和应用
CN106831799A (zh) 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途
ES2362591B1 (es) Compuestos multifuncionales modificadores de la enfermedad de alzheimer para el tratamiento de esta enfermedad.
BR112015009243A2 (pt) composto de amina cíclico fluorosubstituído, método para preparar um composto de amina cíclico fluorosubstituído, composição farmacêutica, inibidor de acetilcolinesterase e uso do composto de amina cíclico fluorosubstituído
JP2023553094A (ja) 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体
Chukhajian et al. A new intramolecular recyclization in water‐base cleavage reaction of 2, 2‐dialkyl‐4‐hydroxymethylbenz [f] iso indolinium bromides and chlorides
Pérez et al. Discovery of substituted phenyl urea derivatives as novel long-acting β2-adrenoreceptor agonists
Asgarshamsi et al. Design, Synthesis, Molecular Docking, and Molecular Dynamics Simulation Studies of Novel 3‐Hydroxypyridine‐4‐one Derivatives as Potential Acetylcholinesterase Inhibitors
Fischer et al. Synthesis and Structural Elucidation of 1, 2‐Disubstituted 3‐Fluoropiperidines
KR101263266B1 (ko) 쿠마린 유도체, 그의 제조 방법 및 그를 포함하는 약제학적 조성물
Hoogendoorn et al. ortho‐Carborane‐Modified N‐Substituted Deoxynojirimycins
WO2009145852A1 (en) Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant